Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of JNJ-56136379 on OC and Midazolam PK
NCT03111511Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bersacapavir in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of Drospirenone at Day 21, Area Under the Analyte Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration of Drospirenone at Day 21 and 7 more. Started Mar 2017; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03111511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111511.